Preclinical data for MDL-001 establish proof-of-concept for an oral therapy targeting HCV/HBV co-infection, a population with an over 100x elevated liver cancer risk.
Model Medicines press release
San Diego, CA, 18 February 2026 — Model Medicines, an AI-native biotechnology company, today announced preclinical data demonstrating that MDL-001 has potent antiviral activity against both hepatitis C virus (HCV) and hepatitis B virus (HBV). These results establish preclinical proof of concept for a single non-nucleoside agent targeting HCV/HBV co-infection, one of the most dangerous and underserved populations in hepatology.
MDL-001 is an oral, direct-acting, broad-spectrum antiviral targeting the Thumb-1 allosteric domain of viral RNA-dependent RNA polymerases. Its novel mechanism enables activity across multiple viral families, including hepatitis viruses and respiratory pathogens, with a pharmacokinetic and safety profile suitable for outpatient use.
Read the full press release here.
Source : Model Medicines
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
The Rockefeller University: A new mouse model of virus-driven liver cancer may open the door to better diagnosis and treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.